| Theme | Advanced Therapy Ulcerative Colitis | |
|---|---|---|
| Title | Leukocytapheresis Therapy for Ulcerative | |
| Publish Date | 1997/09 | |
| Author | Akimitsu Egashira | Fourth Department of Internal Medicine, Hyogo College of Medicine |
| Author | Koji Sawada | Fourth Department of Internal Medicine, Hyogo College of Medicine |
| Author | Takashi Shimoyama | Fourth Department of Internal Medicine, Hyogo College of Medicine |
| [ Summary ] | Recently, a new therapy that called "leukocytapheresis(LCAP)" was developed for inflammatory bowel diseases, especially ulcerative colitis (UC). The aim of LCAP, performed with a leukocyte removal filter, for UC is to control the excessive immune responses responsible for local inflammation. LCAP removes white blood cells such as granulocytes, monocytes, and lymphocytes that may account for the main part of the immune response in local lesions. During intensive therapy, an excellent or moderate clinical response was recognized in 21 of 25 patients (84%) and the excellent or moderate clinical response continued throughout maintenance therapy in 19 of the 25 patients(76%). There was no aggravation in either case. |
|